Semaglutide Impurities, endo-16a-Gln-SMT

Basic Description

Structure and function:
1. endo-16a-Gln-SMT is an impurity of semaglutide with an additional glutamine residue inserted into the side chain of the glycine residue at position 16.
2. It is a GLP-1 receptor agonist that regulates blood glucose levels by mimicking intestinal secretion of glucagon-like peptide-1 (GLP-1).
3. Due to the insertion of an additional amino acid residue, its biological activity and pharmacokinetic properties may differ from those of semaglutide.
In vitro and in vivo studies:
1. In vitro studies have shown that endo-16a-Gln-SMT is still able to bind to and activate the GLP-1 receptor, but its affinity and potency may be reduced.
2. In vivo studies have shown that the hypoglycemic effect of this impurity in animal models is weaker than that of semaglutide, and its half-life may be shorter.
3. Preclinical studies have shown that endo-16a-Gln-SMT may cause adverse reactions or reduced efficacy in some cases.

​ ​Three-letter sequence​

​ ​Single letter sequence​

Molecular formula

Molecular weight

purity

>98%

form

Lyophilized powder

Storage conditions

Store at -20°C/-80°C away from light